MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

P. de la Puente; B. Muz; A. Jin; F. Azab; M. Luderer; N. N. Salama; A. K. Azab

doi:10.1038/BCJ.2016.7

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

P. de la Puente
, B. Muz
, A. Jin
, F. Azab
, M. Luderer
, N. N. Salama
, A. K. Azab

Pharmaceutical and Administrative Sciences Department

Washington University School of Medicine in St. Louis
St. Louis College of Pharmacy
Cairo University Faculty of Pharmacy

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	e399
Journal	Blood Cancer Journal
Volume	6
Issue number	2
DOIs	https://doi.org/10.1038/BCJ.2016.7
State	Published - 2016

ASJC Scopus Subject Areas

Hematology
Oncology

Access to Document

10.1038/BCJ.2016.7

Cite this

@article{8ea822cbfe9b45c988e472efe4db227c,

title = "MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma",

author = "\{de la Puente\}, P. and B. Muz and A. Jin and F. Azab and M. Luderer and Salama, \{N. N.\} and Azab, \{A. K.\}",

year = "2016",

doi = "10.1038/BCJ.2016.7",

language = "English",

volume = "6",

journal = "Blood Cancer Journal",

issn = "2044-5385",

number = "2",

}

TY - JOUR

T1 - MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

AU - de la Puente, P.

AU - Muz, B.

AU - Jin, A.

AU - Azab, F.

AU - Luderer, M.

AU - Salama, N. N.

AU - Azab, A. K.

PY - 2016

Y1 - 2016

UR - https://www.scopus.com/pages/publications/84995423367

UR - https://www.scopus.com/pages/publications/84995423367#tab=citedBy

U2 - 10.1038/BCJ.2016.7

DO - 10.1038/BCJ.2016.7

M3 - Letter

C2 - 26918363

AN - SCOPUS:84995423367

SN - 2044-5385

VL - 6

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 2

M1 - e399

ER -

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this